Transgene Participates in New Cancer Research Consortium
20210901 PERSIST-SEQ EN
By @CcR34Tg|2021-09-01T16:01:41+02:00September 1st, 2021|Invir.IO, Press release|Comments Off on Transgene Participates in New Cancer Research Consortium
3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the [...]
Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
210527 - Transgene BioInvent_BT001 IND_EN
Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
K. Bendjama et al. AACR 2021 Read the abstract here [...]
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 - Transgene Scientific Conferences
Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
20210301 - Transgene BT-001 FPI - EN
Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
20201221 - CTA Approval BT-001 - EN
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
Franck Gallardo, et al. Biomedicines, November 26 2020 - Read [...]
